Nursing care
Potassium-Sparing Diuretics: what to check before you give it
Written and reviewed by Dana Whitfield, RN, MSN · 5 min read · Updated September 2026
Short answer
Potassium-sparing diuretics reduce fluid retention while protecting serum potassium, but that protection is the danger: hyperkalaemia is the defining risk. Check baseline potassium and renal function before the first dose, hold for levels above 5.0 mEq/L, and warn patients off salt substitutes, which are potassium chloride in disguise.
Mechanism, simply
Potassium-sparing diuretics act on the distal convoluted tubule and collecting duct, the last stretch of the nephron where sodium is reabsorbed in exchange for potassium and hydrogen ion excretion. Spironolactone and eplerenone block the aldosterone receptor directly, so aldosterone cannot drive that exchange. Amiloride and triamterene take a different route, blocking the epithelial sodium channel itself, but the outcome is the same.
Because the exchange is interrupted, sodium and water leave in the urine while potassium stays in the blood. This is the opposite pattern to loop and thiazide diuretics, which waste potassium. It is why these drugs are rarely prescribed alone for oedema — the diuretic effect is modest — but are frequently added to a loop diuretic to offset potassium loss, or used specifically for their aldosterone-blocking action in heart failure.
Indications you will see on the ward
Spironolactone appears constantly in heart failure with reduced ejection fraction, where low-dose aldosterone blockade improves survival independent of its diuretic effect — this is the RALES-type indication your patient's cardiologist is chasing, not fluid removal. Eplerenone serves the same role for patients who develop gynaecomastia or menstrual irregularities on spironolactone, since it does not bind progesterone or androgen receptors.
You will also see spironolactone for ascites in cirrhosis, where secondary hyperaldosteronism drives fluid retention, and for resistant hypertension as a fourth-line agent. Amiloride and triamterene turn up mainly combined with hydrochlorothiazide in a single tablet, used to blunt the hypokalaemia that thiazide alone would cause. Off-label, spironolactone is also used for hirsutism and acne in women, exploiting its anti-androgen effect.
Assessment before administration
Pull a baseline serum potassium and creatinine before the first dose and recheck within a week of starting or adjusting the dose, then periodically thereafter. Hold the dose and notify the prescriber if potassium is above 5.0 mEq/L or if renal function has declined, since these drugs are contraindicated in significant renal impairment — potassium has nowhere to go if the kidneys cannot excrete it.
Take a baseline blood pressure and weight, and ask about current medications and diet before you assume the drug is safe to give. A patient on an ACE inhibitor, an ARB, or a potassium supplement is already stacking potassium risk, and a patient eating a high-potassium diet or using a salt substitute is doing the same without knowing it. Confirm the apical pulse and cardiac rhythm history too, since hyperkalaemia's first clinical sign is often cardiac, not renal.
Toxicity and the antidote
Hyperkalaemia is the toxicity that defines this drug class. Early signs are vague — muscle weakness, paraesthesia, fatigue — which is why you rely on the lab value rather than waiting for symptoms. As potassium climbs, watch the ECG for peaked T waves, a widening QRS, and eventually loss of the P wave; these changes can progress to ventricular fibrillation or asystole.
There is no single antidote in the way naloxone reverses opioids. Management is a sequence: IV calcium gluconate to stabilise the cardiac membrane first if the ECG is abnormal, then insulin with dextrose and often a beta-2 agonist to shift potassium into cells, and sodium polystyrene sulfonate or patiromer to remove potassium from the body. Dialysis is the last step for severe or refractory cases. Your job at the bedside is recognising the pattern early and getting the level drawn before it reaches that point.
Interactions that matter
ACE inhibitors and ARBs are the interaction to flag every time, because both drug classes raise potassium through different mechanisms and the combination is common in heart failure regimens. NSAIDs compound the risk further by reducing renal blood flow and prostaglandin-mediated potassium excretion, so a patient reaching for ibuprofen for joint pain is quietly working against their diuretic.
Potassium supplements, whether prescribed or taken independently, should prompt a direct question about why the patient thinks they need one. Trimethoprim, often overlooked because it is an antibiotic rather than a cardiac drug, also spares potassium and has caused dangerous hyperkalaemia when combined with spironolactone in older adults. Digoxin levels can rise with some potassium-sparing diuretics too, so toxicity signs like visual halos or arrhythmia deserve a second look in a patient on both.
What the patient must be told
The instruction that prevents the most harm is also the one patients least expect: no salt substitutes. Products like Lo Salt or Nu-Salt replace sodium chloride with potassium chloride, and a patient using one liberally while on spironolactone can push their potassium into dangerous territory without any change to their prescribed medications. Tell them explicitly, by name, rather than assuming 'avoid extra potassium' will register.
Beyond that, teach patients to report muscle weakness, an irregular heartbeat, or numbness and tingling promptly, and to attend every scheduled blood test even when they feel well, since hyperkalaemia can be silent until it is dangerous. Warn men starting spironolactone that breast tenderness or enlargement can occur and is a reason to discuss switching to eplerenone rather than stopping treatment unprompted. Advise against high-potassium foods in excess — bananas, oranges, potatoes, tomatoes — without turning this into a restrictive diet, since the goal is moderation, not avoidance.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our pharmacology practice questions are the closest set to what this page covers.
One question from the pharmacology set
A client with heart failure is started on furosemide 40 mg PO daily. Which findings should the nurse report to the provider before administering the next dose? Select all that apply.
Rationale
Furosemide is a loop diuretic, so the two things you are watching are potassium and kidney function. A potassium of 2.9 mEq/L is below the 3.5–5.0 reference range and puts the client at risk for dysrhythmia — hold and report. Muscle cramps with palpitations are the clinical face of that same hypokalemia, so they are reported together, not separately. A creatinine that doubles signals the diuresis has outrun renal perfusion. A blood pressure of 132/78 and a 1 kg loss are the expected response to the drug working, not reasons to hold it.
Answer: A, D, E
Common questions
Can potassium-sparing diuretics be given with a potassium supplement?
Generally no. Combining the two stacks two mechanisms that both raise serum potassium, and the combination is a recognised cause of dangerous hyperkalaemia. If a patient is on both, confirm it is intentional and monitored closely, and query the order if it looks like an oversight.
Why is spironolactone given at night sometimes?
It is not a strict rule, but some prescribers time it in the evening to reduce daytime diuresis and nocturia is instead planned around it, or to align with other cardiac medications. Follow the specific order and the patient's usual routine rather than assuming one fixed schedule.
What potassium level should trigger holding the dose?
A level above 5.0 mEq/L should prompt holding the dose and notifying the prescriber, though the exact threshold can vary by institutional protocol and the patient's baseline. Always correlate with the ECG, since a normal level with abnormal cardiac signs still needs urgent attention.
How is spironolactone different from eplerenone in practice?
Both block the aldosterone receptor, but spironolactone also binds progesterone and androgen receptors, causing gynaecomastia, breast tenderness, or menstrual irregularities in some patients. Eplerenone is more receptor-selective and avoids those effects, which is why it is often the substitute when they occur.
Is grapefruit juice a concern with these diuretics?
It is more relevant to eplerenone, which is metabolised by CYP3A4; grapefruit juice can raise eplerenone levels and increase hyperkalaemia risk. Spironolactone and amiloride are not metabolised the same way, so the interaction is drug-specific rather than a rule for the whole class.
More on pharmacology
Guides on this